Unexplained weight loss (UWL), clinically defined as a loss of 5% or more of body weight within a six to twelve-month period, is a challenging diagnostic puzzle. It often indicates serious underlying pathology and necessitates a thorough and systematic approach for accurate diagnosis.
UWL can be attributed to a myriad of causes, most commonly malignancies, gastrointestinal disorders, endocrine diseases, and psychiatric illnesses. Understanding the pathophysiology of these conditions is crucial in formulating a comprehensive diagnostic plan.
A patient-centric, systematic approach is recommended for diagnosing UWL. A detailed history, physical examination, and basic laboratory tests form the cornerstone of this approach. Special attention should be given to age, associated symptoms, and risk factors. In older patients, malignancies and chronic diseases are more prevalent, while in younger patients, psychiatric disorders and malabsorption syndromes should be considered.
While routine imaging is not recommended, it may be warranted in certain cases. For instance, if the clinical history and physical examination suggest a specific organ involvement, targeted imaging can be beneficial. Similarly, in patients with significant weight loss and no clear diagnosis after initial evaluation, computed tomography (CT) of the chest, abdomen, and pelvis may be considered.
Follow-up is crucial in cases of UWL. If initial investigations are inconclusive, patients should be closely monitored for the emergence of new symptoms. This allows for timely intervention and improved patient outcomes.
Diagnosing UWL requires a comprehensive, systematic, and patient-centric approach. Understanding the etiology, adopting an appropriate diagnostic approach, recognizing the role of imaging, and emphasizing the importance of follow-up are all integral to successfully deciphering this enigma. By doing so, clinicians can ensure timely and appropriate management, ultimately improving patient outcomes.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation